8p deletion is strongly linked to poor prognosis in breast cancer

Deletions of chromosome 8p occur frequently in breast cancers, but analyses of its clinical relevance have been limited to small patient cohorts and provided controversial results. A tissue microarray with 2,197 breast cancers was thus analyzed by fluorescence in-situ hybridization using an 8p21 probe in combination with a centromere 8 reference probe. 8p deletions were found in 50% of carcinomas with no special type, 67% of papillary, 28% of tubular, 37% of lobular cancers and 56% of cancers with medullary features. Deletions were always heterozygous. 8p deletion was significantly linked to advanced tumor stage (P < 0.0001), high-grade (P < 0.0001), high tumor cell proliferation (Ki67 Labeling Index; P < 0.0001), and shortened overall survival (P < 0.0001). For example, 8p deletion was seen in 32% of 290 grade 1, 43% of 438 grade 2, and 65% of 427 grade 3 cancers. In addition, 8p deletions were strongly linked to amplification of MYC (P < 0.0001), HER2 (P < 0.0001), and CCND1 (p = 0.001), but inversely associated with ER receptor expression (p = 0.0001). Remarkably, 46.5% of 8p-deleted cancers harbored amplification of at least one of the analyzed genes as compared to 27.5% amplifications in 8p-non-deleted cancers (P < 0.0001). In conclusion, 8p deletion characterizes a subset of particularly aggressive breast cancers. As 8p deletions are easy to analyze, this feature appears to be highly suited for future DNA based prognostic breast cancer panels. The strong link of 8p deletion with various gene amplifications raises the possibility of a role for regulating genomic stability.

[1]  J. Korbel,et al.  Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer , 2014, International journal of cancer.

[2]  J. Kocher,et al.  Genome-Wide Analysis of Loss of Heterozygosity in Breast Infiltrating Ductal Carcinoma Distant Normal Tissue Highlights Arm Specific Enrichment and Expansion across Tumor Stages , 2014, PloS one.

[3]  Wen-li Ma,et al.  The Role of PinX1 in Growth Control of Breast Cancer Cells and Its Potential Molecular Mechanism by mRNA and lncRNA Expression Profiles Screening , 2014, BioMed research international.

[4]  Holger Moch,et al.  Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study , 2013, BMC Cancer.

[5]  C. Croce,et al.  LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer , 2013, Oncotarget.

[6]  J. Lee,et al.  Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma In Situ , 2013, Journal of breast cancer.

[7]  G. Mercado,et al.  Assessment of clinical scoring systems for the diagnosis of Williams-Beuren syndrome. , 2013, Genetics and molecular research : GMR.

[8]  G R Taylor,et al.  Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisation. , 2013, Genomics.

[9]  S. Kurtz,et al.  Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.

[10]  A. Sartori,et al.  Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy. , 2013, Swiss medical weekly.

[11]  C. Morris,et al.  Dual-Color Fluorescence In Situ Hybridization Reveals an Association of Chromosome 8q22 but Not 8p21 Imbalance with High Grade Invasive Breast Carcinoma , 2013, PloS one.

[12]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[13]  Dong Liu,et al.  DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma , 2013, Tumor Biology.

[14]  C. Greenwood,et al.  Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. , 2013, Cancer genetics.

[15]  F. Jänicke,et al.  Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer , 2013, Breast Cancer Research and Treatment.

[16]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[18]  Michael Wigler,et al.  A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions , 2012, Proceedings of the National Academy of Sciences.

[19]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[20]  A. Ashworth,et al.  Therapeutic potential of PARP inhibitors for metastatic breast cancer , 2011, Expert review of anticancer therapy.

[21]  Sehwan Han,et al.  Genomic change of chromosome 8 predicts the response to taxane-based neoadjuvant chemotherapy in node-positive breast cancer. , 2010, Oncology reports.

[22]  V. Speirs,et al.  Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma , 2010, Breast Cancer Research and Treatment.

[23]  V. Bohr,et al.  Roles of Werner syndrome protein in protection of genome integrity. , 2010, DNA repair.

[24]  I. Thompson,et al.  Single and Multivariate Associations of MSR1, ELAC2, and RNASEL with Prostate Cancer in an Ethnic Diverse Cohort of Men , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[25]  G. Sauter,et al.  Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.

[26]  M. Espié,et al.  Breast Intracystic Papillary Carcinoma: An Update , 2009, The breast journal.

[27]  Yoko Ito,et al.  The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene , 2009, Oncogene.

[28]  A. Vincent-Salomon,et al.  8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis , 2009, PloS one.

[29]  Carlos Caldas,et al.  High-resolution array CGH clarifies events occurring on 8p in carcinogenesis , 2008, BMC Cancer.

[30]  M. Bignami,et al.  Werner syndrome helicase activity is essential in maintaining fragile site stability , 2008, The Journal of cell biology.

[31]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Alfons Meindl,et al.  Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. , 2007, Carcinogenesis.

[34]  G. Sauter,et al.  Tissue microarrays for comparing molecular features with proliferation activity in breast cancer , 2006, International journal of cancer.

[35]  Samuel H. Wilson,et al.  The Werner syndrome protein operates in base excision repair and cooperates with DNA polymerase β , 2006, Nucleic acids research.

[36]  M. Cronin,et al.  Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes , 2005, Clinical Cancer Research.

[37]  Gary H Lyman,et al.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.

[38]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[39]  K. Gish,et al.  Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers , 2004, Oncogene.

[40]  G. Meijer,et al.  Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma , 2004, Modern Pathology.

[41]  Jorma Isola,et al.  Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.

[42]  P. V. van Diest,et al.  In lymph node‐negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor , 2003, The Journal of pathology.

[43]  A. Jauch,et al.  Breast cancer in young women (≤35 years): Genomic aberrations detected by comparative genomic hybridization , 2003, International journal of cancer.

[44]  F. Wright,et al.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. , 2003, American journal of human genetics.

[45]  S. Thorgeirsson,et al.  DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity , 2003, Oncogene.

[46]  D. Goudie,et al.  Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer , 2002, The British journal of surgery.

[47]  S. Singletary,et al.  Treatment and outcome of patients with intracystic papillary carcinoma of the breast. , 2002, American journal of surgery.

[48]  S. Devries,et al.  Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. , 2002, Human pathology.

[49]  C. Sheehan,et al.  Comparison of HER-2/ neu Oncogene Amplification Detected by Fluorescence In Situ Hybridization in Lobular and Ductal Breast Cancer , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[50]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[51]  R. Schlenk,et al.  Clinical relevance of genomic aberrations in homogeneously treated high‐risk stage II/III breast cancer patients , 2001, International journal of cancer.

[52]  P. V. van Diest,et al.  Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution , 2001, The Journal of pathology.

[53]  Stefan Handt,et al.  Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization , 2001, The Journal of pathology.

[54]  P. Schlag,et al.  Refined deletion mapping in sporadic breast cancer at chromosomal region 8p12-p21 and association with clinicopathological parameters. , 2000, European journal of cancer.

[55]  Karsten Schlüns,et al.  Patterns of chromosomal imbalances in invasive breast cancer , 2000, International journal of cancer.

[56]  P J Drew,et al.  Genetic changes in breast cancer detected by comparative genomic hybridisation , 2000, International journal of cancer.

[57]  B. Agnarsson,et al.  Chromosome 8p alterations in sporadic andBRCA2 999del5 linked breast cancer , 2000, Journal of medical genetics.

[58]  H Buerger,et al.  Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes , 1999, The Journal of pathology.

[59]  A. Hanby,et al.  Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. , 1999, Cancer research.

[60]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[61]  P. V. van Diest,et al.  Genetic analysis of 53 lymph node‐negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors , 1998, The Journal of pathology.

[62]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[63]  R Anbazhagan,et al.  Allelic loss of chromosomal arm 8p in breast cancer progression. , 1998, The American journal of pathology.

[64]  S. Hilsenbeck,et al.  Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. , 1995, The American journal of pathology.

[65]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[66]  W. Recant,et al.  Loss of heterozygosity from the short arm of chromosome 8 is an early event in breast cancers , 1995, Genes, chromosomes & cancer.

[67]  A. Marchetti,et al.  p53 Mutations and Histologie Type of Invasive Breast Carcinoma , 1993, Cancer research.

[68]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[69]  S. Silverberg,et al.  Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. , 1988, Human pathology.

[70]  P. Rosen,et al.  Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow‐up , 1977, Cancer.

[71]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[72]  Peixin Zhang,et al.  DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[73]  D. Carvalho,et al.  Smith-Magenis syndrome: clinical evaluation in seven Brazilian patients. , 2011, Genetics and molecular research : GMR.

[74]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[75]  A. Kallioniemi.  DNA copy number analysis on tissue microarrays. , 2010, Methods in molecular biology.

[76]  Josef Korinek,et al.  Proceedings of the American Society of Clinical Oncology , 1982 .